# Abzu

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abzu-aps

- Industry: Software
- Headquarters: Copenhagen, Denmark
- Website: www.abzu.ai
- Total disclosed funding: $11M
- Latest round: Seed (Apr 8, 2021)
- Investors on record: 5

## About

Abzu Aps is an innovative company specializing in AI-driven drug design solutions, focused on enhancing RNA therapeutics. Their flagship platform, QLattice®, revolutionizes the drug discovery process by integrating advanced predictive modeling techniques.Founded in 2018 and headquartered in Copenhagen, Denmark, Abzu Aps is dedicated to developing AI solutions for drug discovery. The company has successfully raised EUR 5.8 mn in Seed funding on April 8, 2021, co-led by SEED Capital and supported by returning investors such as Inventure and PreSeed Ventures. Victor Batanero is the founder of Abzu, while Casper Wilstrup and Nika Tsitelashvili currently serve as the company's CEOs.Abzu specializes in the development of AI-driven drug design solutions, with a primary focus on RNA therapeutics. Their flagship product, the QLattice®, serves as an explainable AI platform that enhances the drug discovery process by generating predictive models based on curated data. This approach enables clients to design drug compounds while considering critical factors that traditional methodologies often overlook, such as thermodynamics and genetic variation. Abzu aims to maximize the success rate of drug development by providing clients with ready-to-use compound designs and detailed reports on the selection process. The company primarily serves pharmaceutical and biotechnology firms across Europe and North America, catering to a client base that includes researchers and organizations seeking innovative solutions in drug development.Abzu's revenue model is based on partnerships and direct engagements with clients within the pharmaceutical sector. The company collaborates with clients to offer tailored AI-driven drug design services, which may involve a combination of project-based fees and ongoing consultancy arrangements. These transactions typically encompass the provision of predictive models, data analysis, and experimental design services, all grounded in the principles of their proprietary technologies. Specific pricing structures for their services are determined based on the scope and complexity of each project, ensuring alignment with client needs and objectives. By integrating their unique offerings, such as the QLattice®, into the drug design workflow, Abzu establishes a value-driven relationship with its clients that emphasizes both immediate insights and long-term research benefits.In April 2021, Abzu Aps raised EUR 5.8 mn in Seed funding to accelerate its commercialization within pharmaceutical drug discovery and mature its AI platform for application in other industry verticals. The funding will support the development of new products and the potential expansion into additional markets, reinforcing their commitment to innovate within drug discovery. The company is strategically targeting broader applications of its technology while enhancing its presence in existing markets across Europe and North America.

## Funding rounds

- Seed, Apr 8, 2021, $6.8M — PreSeed Ventures, SEED Capital, Inventure, Vaekstfonden
- Seed, Oct 8, 2019, $1.9M — PreSeed Ventures, Nordic Venture Partners, Inventure
- Seed, Jul 5, 2019, $2M — PreSeed Ventures, Inventure, Vaekstfonden

## Investors

- PreSeed Ventures (https://capitalatlas.ai/funds/preseed-ventures) — Seed
- Inventure (https://capitalatlas.ai/funds/inventure) — Seed
- Vaekstfonden (https://capitalatlas.ai/funds/vaekstfonden) — Seed
- Nordic Venture Partners (https://capitalatlas.ai/funds/nordic-venture-partners) — Seed
- SEED Capital (https://capitalatlas.ai/funds/seed-capital) — Seed